Cardiovascular Diseases Efficacy Evaluation
GemPharmatech offers a comprehensive range of cardiovascular efficacy tests, including tail-cuff blood pressure monitoring, echocardiography, electrocardiogram and pressure-volume catheter. We have successfully developed an array of mouse strains with common cardiovascular diseases. This encompasses atherosclerotic mouse models, hypertensive mouse models and heart failure mouse models generated by surgical procedures or specific gene mutations. Additionally, we can simulate human cardiovascular diseases through medication induction and dietary manipulation. Our services are dedicated to conducting comprehensive efficacy evaluation of candidate drugs, providing accurate data on the therapeutic effects, thus facilitating the development of novel and effective cardiovascular drugs.
-
Heart Failure Models and Efficacy Services
Heart failure refers to the condition in which the heart is functionally impaired and fails to maintain an adequate cardiac output to support the body's normal physiological activities. Both in mouse models and in the clinic, heart failure can be diagnosed based on left ventricular ejection fraction (LVEF). GemPharmatech has developed several heart failure models which exhibit reduced ejection fraction (HFrEF), including the ischemic heart failure model (LAD) and pressure-overload heart failure model (TAC). A model of heart failure with preserved ejection fraction (HFpEF), induced by HFD+L-NAME, is also available.
-
Hypertension Models and Efficacy Services
Hypertension is a medical condition in which the force of blood against the artery walls is consistently too high. In humans, a systolic blood pressure of 140mmHg or higher, and/or a diastolic blood pressure of ≥90mmHg is considered excessive and classified as hypertension. Left untreated, hypertension can lead to serious health problems such as heart disease, stroke, and kidney disease. GemPharmatech provides models and services for hypertension induced by Ang II, L-NAME, or DOCA, as well as the best-in-class humanized AGT mouse model, and spontaneous hypertension mouse model for therapeutic efficacy studies.
-
Atherosclerosis Models and Efficacy Services
Atherosclerosis is a chronic disease caused by the deposition of fat, cholesterol, calcium, and other chemicals in the endothelium of arteries, resulting in the loss of arterial elasticity due to vessel thickening and sclerosis. Once thick plaque substantially blocks the arteries, it can significantly limit blood flow to the vessels serving the tissues, resulting in severe tissue damage. GemPharmatech has developed ApoE knockout models and Ldlr knockout models that can be used to study atherosclerosis and efficacy evaluation services for the related drugs.
-
Advanced Cardiovascular and Metabolic Complication Models and Efficacy Services
Cardiovascular and metabolic complications refer to a group of disorders that occur as a result of underlying cardiovascular and metabolic diseases. The relationship between cardiovascular and metabolic complications is bidirectional. Understanding these complications is crucial for developing effective prevention and treatment strategies in the field of medicine. GemPharmatech offers a validated mouse model of cardio-renal-metabolic syndrome based on the BKS-db mouse which mimics the clinical comorbidity.
-
Hyperlipidemia Models and Efficacy Services
Due to improvements in standard of living and the evolution of average dietary structures, the occurrence of hyperlipidemia (HLP) is increasing. HLP poses a grave threat to human health because it can lead to the development of metabolic disorders in the body, which in turn cause cardiovascular diseases such as atherosclerosis, coronary heart disease, and myocardial infarction. The prevention of hyperlipidemia and the development of related therapeutic medications are of incredible significance.
-
Hypertropic Cardiomyopathy Models and Efficacy Services
Hypertrophic cardiomyopathy (HCM) is a common yet complex genetic heart disorder, which is characterized by hypertrophy of the heart muscle, most commonly affecting the left ventricle. Mutations in genes encoding or related to cardiac sarcomere proteins, such as MYBPC3, MYH7, and TNNT2, can be introduced into animals via gene editing. These mutations disrupt the normal structure and function of the heart muscle, leading to the development of HCM. GemPharmatech has developed Myh6 R404Q and Mybpc3 KO mouse models which express hypertrophic cardiomyopathy phenotypes and can provide drug efficacy evaluation services based on these models.
-
Stroke Models and Efficacy Services
Stroke, also known as a cerebrovascular accident (CVA), is a serious medical condition that occurs when the blood supply to a part of the brain is interrupted or reduced. This deprives brain tissue of oxygen and nutrients, leading to damage and potential loss of brain function. For the study of stroke and development of new therapeutic interventions, GemPharmatech provides thrombotic middle cerebral artery occlusion (MCAO) and non-thrombotic MCAO mouse models, as well as efficacy testing services.
-
Thrombosis Models and Efficacy Services
Thrombosis refers to the formation of a blood clot, known as a thrombus, within a blood vessel. This clotting process can occur in both arteries and veins and has significant impacts on human health. Thrombosis mouse models are essential tools in biomedical research for studying the mechanisms of blood clot formation and evaluating potential anti-thrombotic therapies. GemPharmatech has successfully established an FeCl3-induced carotid thrombosis mouse model and a series of genetically-humanized mouse models that are engineered to express pivotal human coagulation factors, including Factor XI and Factor XII, which can be used in proof-of-concept studies.